By otakuyassine3@gmail.com 
Franklin Resources Inc. increased its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 332,405 shares of the biotechnology company’s stock after purchasing an additional 26,668 shares during the period. Franklin Resources Inc. owned about 0.59% of Repligen worth $47,551,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Toronto Dominion Bank increased its holdings in shares of Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 75 shares during the period. DekaBank Deutsche Girozentrale increased its position in Repligen by 1.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares during the last quarter. MML Investors Services LLC raised its position in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after acquiring an additional 89 shares in the last quarter. Ballentine Partners LLC raised its holdings in shares of Repligen by 6.2% during the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 105 shares in the last quarter. Finally, CWM LLC lifted its stake in shares of Repligen by 36.3% in the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 114 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group started coverage on Repligen in a research report on Tuesday. They issued a “hold” rating and a $165.00 price objective for the company. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday. They issued a “hold” rating and a $165.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $185.20.
Read Our Latest Analysis on Repligen
Repligen Price Performance
Shares of Repligen stock opened at $158.14 on Wednesday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The firm’s 50-day moving average price is $143.15 and its two-hundred day moving average price is $141.68. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of -427.41, a P/E/G ratio of 4.64 and a beta of 0.96.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the company earned $0.23 EPS. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. On average, equities analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Recommended Stories
Receive News & Ratings for Repligen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Repligen and related companies with MarketBeat.com’s FREE daily email newsletter.